相关实验视频

Updated: Jun 23, 2025

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

结直肠癌中的免疫检查点抑制剂:局限性和挑战

Suying Yan¹, Wanting Wang¹, Zhiqiang Feng¹

¹School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Frontiers in immunology

|June 26, 2024

概括

免疫检查点抑制剂 (ICI) 对结直肠癌 (CRC) 是有前途的,但疗效因患者的亚型而异,获得的耐药性是一个问题. 未来的战略涉及更好的生物标志物和组合疗法,以改善结果.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

结肠直肠癌 (CRC) 患病率和转移率很高,目前的治疗成功程度有限.
免疫检查点抑制剂 (ICI) 通过防止瘤免疫逃避,提供了一种新的治疗途径.
在CRC中的ICI疗效在微卫星不稳定性高 (MSI-H) 的微卫星稳定 (MSS) 亚型相比显著更高.

研究的目的:

审查ICI在结直肠癌中的临床疗效.
讨论CRC中对ICI获得的耐药性机制.
总结有害影响,并提出未来的研究方向.

主要方法:

在CRC中对当前ICI临床数据的文献综述.
对ICI耐药性的基础机制的分析.
报告的不良事件的总结.

主要成果:

在MSI-H CRC中,ICI是有效的,但在MSS CRC中效果较差.
获得性耐药机制包括瘤抗原呈现缺陷,IFN-λ反应受损,细胞因子失调和代谢变化.
在CRC患者中记录了ICI的不良影响.

结论:

在CRC中ICI的未来依赖于开发预测生物标志物和组合疗法.
解决耐药性机制对于将ICI的好处扩展到更多的CRC患者至关重要.
需要有针对性的解决问题的方法来提高ICI在CRC治疗中的有效性.

关键词:

生物标志物生物标志物结肠直肠癌是什么意思药物耐药性耐药性药物耐药性免疫检查点抑制剂免疫检查点抑制剂微卫星的不稳定性

更多相关视频

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...